EQS Newswire / 13/02/2023 / 09:59 UTC+8 Suzhou, February 10, 2023 – Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced the positive top-line results from the U.S. Phase I clinical trial of GT20029, a Kintor Pharma in-house developed and fully owned proteolysis targeting chimera (PROTAC) compound. […]
Tag: kintor
Kintor Pharma Announces Oral Presentation at ASH 2022 Highlighting the Data from Novel Dual C-Myc-GSPT1 Degrader GT19715
EQS Newswire / 10/11/2022 / 10:09 UTC+8 Kintor Pharma Announces Oral Presentation at ASH 2022 Highlighting the Data from Novel Dual C-Myc-GSPT1 Degrader GT19715 Suzhou, November 10, 2022 – Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the results from the novel […]
Kintor 2022 Interim Results: Pruxelutamide and KX-826 show positive results, business value has been presented
EQS Newswire / 30/08/2022 / 11:13 UTC+8 Kintor 2022 Interim Results: Pruxelutamide and KX-826 show positive results, business value has been presented Suzhou, August 29, 2022 – Kintor Pharmaceutical Limited (“Kintor Pharma” or “the Company”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced its 2022 interim results […]
Kintor Pharma Announces 2021 Interim Results
SUZHOU, CHINA, Aug 30, 2021 – (ACN Newswire via SEAPRWire.com) – Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced its 2021 interim results and released an update on its recent progress in clinical development, commercialization (including license-out and production capacity expansion), and activities […]